 Cory Dunnick
Concepts (327)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Allergic Contact | 43 | 2025 | 73 | 12.910 |
Why?
| | Dermatology | 28 | 2024 | 127 | 6.870 |
Why?
| | Patch Tests | 36 | 2025 | 57 | 6.370 |
Why?
| | Allergens | 31 | 2025 | 409 | 4.190 |
Why?
| | Dermatitis, Occupational | 11 | 2024 | 14 | 4.170 |
Why?
| | Skin Diseases | 11 | 2021 | 149 | 2.260 |
Why?
| | North America | 26 | 2025 | 313 | 2.150 |
Why?
| | Dermatitis, Irritant | 4 | 2021 | 10 | 1.670 |
Why?
| | Sunscreening Agents | 6 | 2024 | 25 | 1.490 |
Why?
| | Soaps | 3 | 2020 | 10 | 1.390 |
Why?
| | Education, Medical, Undergraduate | 4 | 2019 | 188 | 1.370 |
Why?
| | Skin Neoplasms | 12 | 2024 | 855 | 1.270 |
Why?
| | Melanoma | 10 | 2024 | 760 | 1.220 |
Why?
| | Dermatitis, Contact | 2 | 2020 | 17 | 1.200 |
Why?
| | Dermatologic Agents | 3 | 2024 | 70 | 1.150 |
Why?
| | Students, Medical | 4 | 2021 | 348 | 1.070 |
Why?
| | Curriculum | 5 | 2019 | 992 | 1.040 |
Why?
| | Pigmentation Disorders | 2 | 2024 | 9 | 1.020 |
Why?
| | Schools, Medical | 2 | 2019 | 147 | 1.020 |
Why?
| | Cosmetics | 2 | 2022 | 9 | 0.960 |
Why?
| | Dermatitis, Photoallergic | 1 | 2024 | 3 | 0.910 |
Why?
| | Irritants | 2 | 2021 | 43 | 0.880 |
Why?
| | Surface-Active Agents | 2 | 2022 | 91 | 0.870 |
Why?
| | Telemedicine | 7 | 2020 | 862 | 0.870 |
Why?
| | Hand Dermatoses | 2 | 2021 | 7 | 0.860 |
Why?
| | Music | 2 | 2021 | 43 | 0.860 |
Why?
| | Alopecia Areata | 2 | 2021 | 13 | 0.850 |
Why?
| | Leprosy | 3 | 2020 | 24 | 0.850 |
Why?
| | Nickel | 5 | 2025 | 62 | 0.820 |
Why?
| | Anti-Infective Agents, Local | 2 | 2020 | 40 | 0.800 |
Why?
| | Humans | 104 | 2025 | 137585 | 0.790 |
Why?
| | Retrospective Studies | 32 | 2024 | 15657 | 0.760 |
Why?
| | Hair Preparations | 1 | 2021 | 8 | 0.730 |
Why?
| | Occupations | 1 | 2021 | 49 | 0.710 |
Why?
| | Skin Pigmentation | 1 | 2021 | 49 | 0.700 |
Why?
| | Eczema | 1 | 2021 | 69 | 0.690 |
Why?
| | Psoriasis | 5 | 2021 | 102 | 0.690 |
Why?
| | Hand Hygiene | 1 | 2020 | 9 | 0.680 |
Why?
| | Facial Dermatoses | 4 | 2021 | 16 | 0.670 |
Why?
| | Carbanilides | 1 | 2019 | 3 | 0.650 |
Why?
| | Triclosan | 1 | 2019 | 10 | 0.650 |
Why?
| | Severity of Illness Index | 5 | 2018 | 2828 | 0.640 |
Why?
| | Education, Medical | 2 | 2019 | 266 | 0.620 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1171 | 0.580 |
Why?
| | Cold Injury | 1 | 2017 | 1 | 0.570 |
Why?
| | Internship and Residency | 8 | 2018 | 1147 | 0.560 |
Why?
| | Mountaineering | 1 | 2017 | 40 | 0.550 |
Why?
| | Global Health | 9 | 2020 | 386 | 0.550 |
Why?
| | Weather | 1 | 2017 | 40 | 0.550 |
Why?
| | Patient Satisfaction | 3 | 2018 | 660 | 0.530 |
Why?
| | United States | 26 | 2024 | 14841 | 0.510 |
Why?
| | Public Opinion | 1 | 2016 | 65 | 0.500 |
Why?
| | Ultraviolet Rays | 2 | 2017 | 396 | 0.480 |
Why?
| | Keloid | 1 | 2015 | 7 | 0.480 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2015 | 20 | 0.470 |
Why?
| | Physical Examination | 1 | 2016 | 241 | 0.470 |
Why?
| | Thiazoles | 3 | 2025 | 123 | 0.470 |
Why?
| | Quality of Life | 3 | 2020 | 2892 | 0.460 |
Why?
| | Career Choice | 2 | 2016 | 219 | 0.460 |
Why?
| | Prevalence | 10 | 2024 | 2734 | 0.460 |
Why?
| | Clinical Competence | 4 | 2019 | 1118 | 0.440 |
Why?
| | Petrolatum | 3 | 2023 | 3 | 0.430 |
Why?
| | Dermatitis, Atopic | 2 | 2021 | 329 | 0.430 |
Why?
| | Electronic Prescribing | 1 | 2013 | 3 | 0.430 |
Why?
| | Female | 37 | 2025 | 73304 | 0.420 |
Why?
| | Male | 34 | 2025 | 67762 | 0.410 |
Why?
| | Alopecia | 2 | 2023 | 32 | 0.390 |
Why?
| | Societies, Medical | 5 | 2020 | 820 | 0.390 |
Why?
| | Cannabinoids | 3 | 2020 | 161 | 0.380 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1587 | 0.380 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1313 | 0.370 |
Why?
| | Young Adult | 13 | 2025 | 13209 | 0.370 |
Why?
| | Piperidines | 2 | 2024 | 206 | 0.360 |
Why?
| | Dermatitis, Seborrheic | 2 | 2021 | 4 | 0.360 |
Why?
| | Internet | 5 | 2018 | 655 | 0.360 |
Why?
| | Adult | 25 | 2025 | 37929 | 0.350 |
Why?
| | Education, Medical, Graduate | 1 | 2015 | 486 | 0.330 |
Why?
| | Pyrimidines | 2 | 2024 | 470 | 0.320 |
Why?
| | Cross-Sectional Studies | 11 | 2024 | 5472 | 0.310 |
Why?
| | Consumer Product Safety | 1 | 2009 | 33 | 0.310 |
Why?
| | Drug Industry | 3 | 2019 | 111 | 0.310 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1483 | 0.300 |
Why?
| | Skin | 3 | 2021 | 752 | 0.300 |
Why?
| | United States Food and Drug Administration | 2 | 2019 | 208 | 0.290 |
Why?
| | Quality Improvement | 2 | 2016 | 1178 | 0.290 |
Why?
| | Middle Aged | 16 | 2025 | 33479 | 0.270 |
Why?
| | Adolescent | 10 | 2024 | 21513 | 0.270 |
Why?
| | Adhesives | 2 | 2024 | 14 | 0.270 |
Why?
| | Administration, Topical | 2 | 2024 | 151 | 0.270 |
Why?
| | Conflict of Interest | 2 | 2019 | 130 | 0.260 |
Why?
| | Publishing | 2 | 2019 | 147 | 0.260 |
Why?
| | Child | 9 | 2024 | 21935 | 0.250 |
Why?
| | Electronic Health Records | 1 | 2013 | 1069 | 0.240 |
Why?
| | Incidence | 4 | 2020 | 2804 | 0.240 |
Why?
| | Trace Elements | 1 | 2006 | 51 | 0.240 |
Why?
| | Glucosides | 2 | 2022 | 44 | 0.240 |
Why?
| | Mentha piperita | 1 | 2024 | 1 | 0.230 |
Why?
| | Photosensitivity Disorders | 1 | 2024 | 9 | 0.230 |
Why?
| | Janus Kinase Inhibitors | 1 | 2024 | 26 | 0.230 |
Why?
| | Biomedical Research | 3 | 2016 | 692 | 0.220 |
Why?
| | Plant Oils | 1 | 2024 | 31 | 0.220 |
Why?
| | Administration, Cutaneous | 1 | 2024 | 129 | 0.220 |
Why?
| | Pyrroles | 2 | 2024 | 213 | 0.220 |
Why?
| | Construction Industry | 1 | 2024 | 18 | 0.220 |
Why?
| | Health Education | 2 | 2017 | 341 | 0.210 |
Why?
| | Health Personnel | 2 | 2020 | 710 | 0.210 |
Why?
| | Hair Dyes | 1 | 2023 | 3 | 0.210 |
Why?
| | Chlorhexidine | 2 | 2023 | 24 | 0.210 |
Why?
| | Periodicals as Topic | 2 | 2018 | 211 | 0.210 |
Why?
| | Cost of Illness | 5 | 2020 | 308 | 0.210 |
Why?
| | Drugs, Generic | 1 | 2023 | 22 | 0.200 |
Why?
| | Colorado | 4 | 2019 | 4565 | 0.200 |
Why?
| | Aged | 10 | 2025 | 23961 | 0.190 |
Why?
| | Sunburn | 2 | 2019 | 26 | 0.190 |
Why?
| | Resins, Plant | 1 | 2021 | 5 | 0.190 |
Why?
| | Dental Implants | 1 | 2022 | 11 | 0.190 |
Why?
| | Plant Extracts | 2 | 2021 | 202 | 0.190 |
Why?
| | Contact Lens Solutions | 1 | 2021 | 1 | 0.190 |
Why?
| | Dermatitis, Phototoxic | 1 | 2021 | 3 | 0.180 |
Why?
| | Palmitic Acids | 1 | 2021 | 10 | 0.180 |
Why?
| | Treatment Outcome | 5 | 2024 | 10811 | 0.180 |
Why?
| | Ethanolamines | 1 | 2021 | 17 | 0.180 |
Why?
| | Ammonium Sulfate | 1 | 2021 | 13 | 0.180 |
Why?
| | Registries | 3 | 2021 | 2035 | 0.180 |
Why?
| | Office Visits | 2 | 2018 | 93 | 0.180 |
Why?
| | Aircraft | 1 | 2021 | 22 | 0.180 |
Why?
| | Dental Materials | 1 | 2022 | 57 | 0.180 |
Why?
| | Clothing | 1 | 2021 | 22 | 0.180 |
Why?
| | Carcinoma, Basal Cell | 3 | 2020 | 75 | 0.180 |
Why?
| | Hydrogen Peroxide | 1 | 2023 | 328 | 0.180 |
Why?
| | Coloring Agents | 1 | 2021 | 87 | 0.180 |
Why?
| | Ophthalmic Solutions | 1 | 2021 | 75 | 0.180 |
Why?
| | Occupational Exposure | 2 | 2024 | 341 | 0.180 |
Why?
| | Amides | 1 | 2021 | 93 | 0.170 |
Why?
| | Oxidants | 1 | 2021 | 111 | 0.170 |
Why?
| | Personal Protective Equipment | 1 | 2021 | 52 | 0.170 |
Why?
| | Subcutaneous Tissue | 1 | 2020 | 24 | 0.170 |
Why?
| | Age Distribution | 2 | 2019 | 392 | 0.170 |
Why?
| | Endemic Diseases | 1 | 2020 | 32 | 0.160 |
Why?
| | Benzethonium | 1 | 2019 | 1 | 0.160 |
Why?
| | Health Care Costs | 2 | 2015 | 398 | 0.160 |
Why?
| | Physicians | 2 | 2019 | 910 | 0.160 |
Why?
| | Masks | 1 | 2020 | 63 | 0.160 |
Why?
| | Xylenes | 1 | 2019 | 9 | 0.160 |
Why?
| | Communicable Disease Control | 1 | 2020 | 82 | 0.160 |
Why?
| | Benzalkonium Compounds | 1 | 2019 | 15 | 0.160 |
Why?
| | Marketing | 1 | 2019 | 30 | 0.160 |
Why?
| | Developed Countries | 2 | 2017 | 39 | 0.160 |
Why?
| | Child, Preschool | 4 | 2024 | 11074 | 0.160 |
Why?
| | Chemoprevention | 2 | 2016 | 92 | 0.160 |
Why?
| | Consultants | 1 | 2019 | 13 | 0.160 |
Why?
| | Cannabidiol | 1 | 2021 | 119 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 250 | 0.150 |
Why?
| | Authorship | 1 | 2019 | 53 | 0.150 |
Why?
| | Bibliometrics | 1 | 2019 | 63 | 0.150 |
Why?
| | Drug Approval | 1 | 2019 | 88 | 0.150 |
Why?
| | Financial Support | 1 | 2018 | 22 | 0.150 |
Why?
| | Primary Prevention | 1 | 2020 | 196 | 0.150 |
Why?
| | Quality of Health Care | 2 | 2013 | 642 | 0.150 |
Why?
| | Consumer Health Information | 1 | 2018 | 47 | 0.150 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 2018 | 5 | 0.140 |
Why?
| | Down Syndrome | 1 | 2024 | 496 | 0.140 |
Why?
| | Water | 1 | 2021 | 460 | 0.140 |
Why?
| | Video Recording | 1 | 2018 | 180 | 0.140 |
Why?
| | Hyperpigmentation | 1 | 2018 | 26 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2019 | 233 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.140 |
Why?
| | Developing Countries | 2 | 2017 | 307 | 0.140 |
Why?
| | Environmental Monitoring | 1 | 2020 | 370 | 0.140 |
Why?
| | Outpatients | 1 | 2020 | 396 | 0.130 |
Why?
| | Social Networking | 1 | 2017 | 33 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2020 | 5778 | 0.130 |
Why?
| | Photography | 1 | 2017 | 96 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2020 | 683 | 0.130 |
Why?
| | Travel | 1 | 2017 | 130 | 0.130 |
Why?
| | Substance P | 1 | 1996 | 36 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2020 | 956 | 0.130 |
Why?
| | Sex Factors | 2 | 2020 | 2071 | 0.130 |
Why?
| | Micronutrients | 1 | 2016 | 92 | 0.120 |
Why?
| | Age Factors | 1 | 2023 | 3295 | 0.120 |
Why?
| | Reward | 1 | 2018 | 244 | 0.120 |
Why?
| | Access to Information | 1 | 2016 | 49 | 0.120 |
Why?
| | Ear Auricle | 1 | 2015 | 10 | 0.120 |
Why?
| | Adjuvants, Immunologic | 1 | 2016 | 226 | 0.120 |
Why?
| | Community Health Services | 1 | 2017 | 227 | 0.120 |
Why?
| | Scalp | 1 | 2015 | 35 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Neovascularization, Physiologic | 1 | 1996 | 179 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Keratinocytes | 1 | 2016 | 249 | 0.120 |
Why?
| | Mobile Applications | 1 | 2018 | 183 | 0.120 |
Why?
| | Shoulder | 1 | 2015 | 89 | 0.110 |
Why?
| | Parkinson Disease | 1 | 2020 | 493 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2015 | 220 | 0.110 |
Why?
| | National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.) | 1 | 2014 | 1 | 0.110 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2015 | 128 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2017 | 512 | 0.110 |
Why?
| | Chlorpromazine | 1 | 2014 | 5 | 0.110 |
Why?
| | Carcinoma | 1 | 2016 | 240 | 0.110 |
Why?
| | Corneal Opacity | 1 | 2014 | 7 | 0.110 |
Why?
| | Research Support as Topic | 1 | 2015 | 119 | 0.110 |
Why?
| | Disease Management | 1 | 2018 | 628 | 0.110 |
Why?
| | Financing, Government | 1 | 2014 | 47 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2018 | 546 | 0.110 |
Why?
| | Cannabis | 1 | 2021 | 494 | 0.110 |
Why?
| | Wound Healing | 1 | 1996 | 331 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 350 | 0.100 |
Why?
| | Universities | 1 | 2016 | 433 | 0.100 |
Why?
| | Cornea | 1 | 2014 | 138 | 0.100 |
Why?
| | Altitude | 1 | 2017 | 488 | 0.100 |
Why?
| | Social Support | 1 | 2017 | 618 | 0.100 |
Why?
| | Research Report | 1 | 2013 | 83 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3284 | 0.100 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 445 | 0.100 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 194 | 0.090 |
Why?
| | Burns | 1 | 1996 | 325 | 0.090 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 447 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Acne Vulgaris | 1 | 2011 | 29 | 0.090 |
Why?
| | Infant | 3 | 2024 | 9465 | 0.090 |
Why?
| | Cobalt | 2 | 2025 | 52 | 0.090 |
Why?
| | Perfume | 2 | 2024 | 4 | 0.090 |
Why?
| | Quality-Adjusted Life Years | 3 | 2017 | 113 | 0.090 |
Why?
| | Social Media | 1 | 2014 | 158 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1477 | 0.080 |
Why?
| | Needs Assessment | 1 | 2011 | 376 | 0.080 |
Why?
| | Databases, Factual | 3 | 2020 | 1357 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 2069 | 0.080 |
Why?
| | Information Dissemination | 1 | 2010 | 218 | 0.070 |
Why?
| | Risk Factors | 4 | 2021 | 10388 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2010 | 766 | 0.060 |
Why?
| | Disability Evaluation | 2 | 2017 | 290 | 0.050 |
Why?
| | Phenylenediamines | 1 | 2023 | 10 | 0.050 |
Why?
| | Preservatives, Pharmaceutical | 1 | 2023 | 26 | 0.050 |
Why?
| | Benzophenones | 1 | 2023 | 16 | 0.050 |
Why?
| | Canada | 1 | 2024 | 418 | 0.050 |
Why?
| | Interferon-beta | 1 | 2023 | 92 | 0.050 |
Why?
| | Lanolin | 1 | 2022 | 1 | 0.050 |
Why?
| | Dentistry | 1 | 2022 | 10 | 0.050 |
Why?
| | Europe | 1 | 2023 | 414 | 0.050 |
Why?
| | Chorioallantoic Membrane | 1 | 2021 | 3 | 0.050 |
Why?
| | Spider Bites | 1 | 2001 | 9 | 0.040 |
Why?
| | Patient-Centered Care | 2 | 2018 | 530 | 0.040 |
Why?
| | Neck | 1 | 2021 | 101 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2021 | 282 | 0.040 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1129 | 0.040 |
Why?
| | Global Burden of Disease | 1 | 2020 | 24 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 179 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2021 | 1092 | 0.040 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 99 | 0.040 |
Why?
| | Prognosis | 2 | 2018 | 4030 | 0.040 |
Why?
| | Sunbathing | 1 | 2018 | 13 | 0.040 |
Why?
| | Drug Resistance, Bacterial | 1 | 2020 | 186 | 0.040 |
Why?
| | Manufacturing Industry | 1 | 2018 | 4 | 0.040 |
Why?
| | Autoimmunity | 1 | 2024 | 908 | 0.040 |
Why?
| | Dermatologists | 1 | 2018 | 6 | 0.040 |
Why?
| | Equipment and Supplies | 1 | 2018 | 42 | 0.040 |
Why?
| | Aerosols | 1 | 2019 | 176 | 0.040 |
Why?
| | Transportation | 1 | 2018 | 53 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 816 | 0.040 |
Why?
| | Time Factors | 2 | 2019 | 6828 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2018 | 329 | 0.040 |
Why?
| | Thorax | 1 | 2018 | 50 | 0.040 |
Why?
| | China | 1 | 2018 | 217 | 0.030 |
Why?
| | Efficiency, Organizational | 1 | 2018 | 140 | 0.030 |
Why?
| | Smartphone | 1 | 2018 | 91 | 0.030 |
Why?
| | Polypodium | 1 | 2016 | 1 | 0.030 |
Why?
| | Patient Care | 1 | 2018 | 111 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2016 | 10 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1066 | 0.030 |
Why?
| | Autoantibodies | 1 | 2024 | 1496 | 0.030 |
Why?
| | Balsams | 1 | 2016 | 2 | 0.030 |
Why?
| | Bacitracin | 1 | 2016 | 6 | 0.030 |
Why?
| | Neomycin | 1 | 2016 | 7 | 0.030 |
Why?
| | p-Aminohippuric Acid | 1 | 1996 | 6 | 0.030 |
Why?
| | Propylene Glycol | 1 | 2016 | 10 | 0.030 |
Why?
| | Culture Techniques | 1 | 1996 | 81 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1060 | 0.030 |
Why?
| | Ketoglutaric Acids | 1 | 1996 | 16 | 0.030 |
Why?
| | 2,4-Dichlorophenoxyacetic Acid | 1 | 1996 | 13 | 0.030 |
Why?
| | Cytokines | 1 | 2024 | 2085 | 0.030 |
Why?
| | Research Design | 1 | 2023 | 1139 | 0.030 |
Why?
| | Community-Institutional Relations | 1 | 2017 | 98 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 73 | 0.030 |
Why?
| | Formaldehyde | 1 | 2016 | 63 | 0.030 |
Why?
| | Neuropeptides | 1 | 1996 | 73 | 0.030 |
Why?
| | Waiting Lists | 1 | 2018 | 266 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 849 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1622 | 0.030 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2020 | 394 | 0.030 |
Why?
| | Gold | 1 | 2016 | 118 | 0.030 |
Why?
| | Personnel Selection | 1 | 2016 | 78 | 0.030 |
Why?
| | Syphilis | 1 | 2014 | 32 | 0.030 |
Why?
| | Measles | 1 | 2014 | 46 | 0.030 |
Why?
| | Chickenpox | 1 | 2014 | 83 | 0.030 |
Why?
| | Leadership | 1 | 2018 | 388 | 0.030 |
Why?
| | Dengue | 1 | 2014 | 80 | 0.030 |
Why?
| | Health Communication | 1 | 2014 | 43 | 0.030 |
Why?
| | Patient Advocacy | 1 | 2014 | 76 | 0.030 |
Why?
| | Faculty, Medical | 1 | 2016 | 283 | 0.020 |
Why?
| | Health Status | 1 | 2018 | 792 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2074 | 0.020 |
Why?
| | Chronic Disease | 1 | 2018 | 1793 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2015 | 351 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1996 | 1738 | 0.020 |
Why?
| | Visual Acuity | 1 | 2014 | 356 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 565 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2018 | 986 | 0.020 |
Why?
| | Schizophrenia | 1 | 2014 | 439 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1809 | 0.020 |
Why?
| | Medicaid | 1 | 2013 | 435 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3457 | 0.020 |
Why?
| | Kidney | 1 | 1996 | 1468 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1946 | 0.020 |
Why?
| | Medicare | 1 | 2013 | 773 | 0.020 |
Why?
| | Pregnancy | 1 | 2020 | 6763 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7604 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7635 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2016 | 6079 | 0.010 |
Why?
| | Mice | 1 | 2017 | 17787 | 0.010 |
Why?
| | Animals | 2 | 2017 | 36940 | 0.010 |
Why?
| | Ouabain | 1 | 1996 | 16 | 0.010 |
Why?
| | Glutarates | 1 | 1996 | 10 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1996 | 265 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2057 | 0.010 |
Why?
| | Rats | 1 | 1996 | 5647 | 0.000 |
Why?
|
|
Dunnick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|